Close Menu
GeekBlog

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    I tried Tecno’s modular phone concept at MWC – and it quickly got weird

    March 4, 2026

    USB Hubs Can Save You Lots of Hassles—Here Are 5 We Like Best in 2026

    March 4, 2026

    Google and Epic look to bury the hatchet with new app store settlement

    March 4, 2026
    Facebook X (Twitter) Instagram Threads
    GeekBlog
    • Home
    • Mobile
    • Tech News
    • Blog
    • How-To Guides
    • AI & Software
    Facebook
    GeekBlog
    Home»Blog»FDA approves Evita Solutions' generic mifepristone amid conservative backlash
    Blog

    FDA approves Evita Solutions' generic mifepristone amid conservative backlash

    Michael ComaousBy Michael ComaousOctober 3, 20252 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
    FDA approves Evita Solutions' generic mifepristone amid conservative backlash
    Share
    Facebook Twitter LinkedIn Pinterest Email Copy Link

    The Food and Drug Administration approved another generic version of the abortion pill mifepristone last month, drawing criticism from abortion opponents and some Republican lawmakers [pbs.org#1][cbsnews.com#4][axios.com#5]. The newly approved version is made by Evita Solutions, which highlighted the product on its website this week, and federal health officials emphasized that the FDA has limited discretion by law when a generic matches the original drug [axios.com#5].

    Highlights:

    • Who was approved: The FDA last month approved a generic mifepristone made by Evita Solutions, which the company promoted on its website this week [axios.com#5].
    • Approval mechanics: Generic approvals focus on whether a copycat matches the original, giving the FDA very limited discretion under federal law [axios.com#5].
    • Conservative reaction: Abortion opponents, including Susan B. Anthony Pro-Life America, criticized the move, and Sen. Josh Hawley voiced distrust in FDA leadership [axios.com#5][cbsnews.com#4][pbs.org#1].
    • HHS position: An HHS spokesman said the agency has 'very limited discretion' in deciding whether to approve a generic drug [axios.com#5].
    • Policy context: The approval follows statements from Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary that they were studying adding new safety limits to mifepristone [axios.com#5][nypost.com#3].

    I have lost confidence in the leadership at FDA. – Sen. Josh Hawley

    Perspectives:

    • HHS spokesman Andrew Nixon: Said the FDA has very limited discretion by law when deciding whether to approve a generic drug. (Axios)
    • Susan B. Anthony Pro-Life America: Called the decision 'unconscionable.'. (Axios)
    • Sen. Josh Hawley: Criticized the agency’s leadership following the approval. (Axios)
    • HHS Secretary Robert F. Kennedy Jr.: Indicated the FDA was bound by federal law to approve the drug, even as officials study safety limits. (New York Post)

    Sources:

    • FDA approves another generic abortion pill, prompting conservative backlash – pbs.org
    • ‘SHOCKING’: FDA Approves New Abortion Drug – dailysignal.com
    • FDA approves another abortion pill after RFK Jr. pledged to review safety of mifepristone – outraging conservatives – nypost.com
    • FDA approves another generic abortion pill – cbsnews.com
    • FDA okays new generic abortion drug, outraging conservatives – axios.com
    approves backlash conservative Evita FDA generic mifepristone Solutions039
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email Copy Link
    Previous ArticleArs Live: Is the AI bubble about to pop? A live chat with Ed Zitron.
    Next Article China Is Leading the World in the Clean Energy Transition. Here’s What That Looks Like
    Michael Comaous
    • Website

    Michael Comaous is a dedicated professional with a passion for technology, innovation, and creative problem-solving. Over the years, he has built experience across multiple industries, combining strategic thinking with hands-on expertise to deliver meaningful results. Michael is known for his curiosity, attention to detail, and ability to explain complex topics in a clear and approachable way. Whether he’s working on new projects, writing, or collaborating with others, he brings energy and a forward-thinking mindset to everything he does.

    Related Posts

    4 Mins Read

    Magic Mushroom Ingredient Passes Major Test, Paving Way for FDA Approval

    2 Mins Read

    FDA refuses to review Moderna’s mRNA flu vaccine

    6 Mins Read

    Amazon Ring’s Super Bowl ad sparks backlash amid fears of mass surveillance

    2 Mins Read

    Conservative lawmakers want porn taxes. Critics say they’re unconstitutional.

    4 Mins Read

    Conservative Lawmakers Want Porn Taxes. Critics Say They’re Unconstitutional

    3 Mins Read

    Trump sends 200 Texas Guard to Illinois amid lawsuit

    Top Posts

    Discord will require a face scan or ID for full access next month

    February 9, 2026761 Views

    The Mesh Router Placement Strategy That Finally Gave Me Full Home Coverage

    August 4, 2025564 Views

    Past Wordle answers – all solutions so far, alphabetical and by date

    August 1, 2025230 Views
    Stay In Touch
    • Facebook

    Subscribe to Updates

    Get the latest tech news from FooBar about tech, design and biz.

    Most Popular

    Discord will require a face scan or ID for full access next month

    February 9, 2026761 Views

    The Mesh Router Placement Strategy That Finally Gave Me Full Home Coverage

    August 4, 2025564 Views

    Past Wordle answers – all solutions so far, alphabetical and by date

    August 1, 2025230 Views
    Our Picks

    I tried Tecno’s modular phone concept at MWC – and it quickly got weird

    March 4, 2026

    USB Hubs Can Save You Lots of Hassles—Here Are 5 We Like Best in 2026

    March 4, 2026

    Google and Epic look to bury the hatchet with new app store settlement

    March 4, 2026

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    Facebook
    • About Us
    • Contact us
    • Privacy Policy
    • Disclaimer
    • Terms and Conditions
    © 2026 GeekBlog

    Type above and press Enter to search. Press Esc to cancel.

    Ad Blocker Enabled!
    Ad Blocker Enabled!
    Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.